Regeneron Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2022

Click here to view more REGN transcripts

Mar 15, 2022 / 02:00PM GMT
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst

Great. Thank you, Andrew. Really appreciate it. Thanks for helping set this up and making it so easy. Hi, everybody. We're getting to the middle or close to the middle part of the day in the first day of the Oppenheimer Healthcare Conference. We have Regeneron also presenting at this fireside chat. Representing Regeneron is Dr. Izzy Lowy, who is the Head of Translational and Clinical Oncology at Regeneron. I'm sure quite a few have heard him speak before at various investor events. I have also. So it's a real pleasure to have you with us today, Dr. Lowy. Really appreciate it.

Israel Lowy - Regeneron Pharmaceuticals, Inc. - SVP of Translational & Clinical Sciences - Oncology

Well, thank you very much. It's a pleasure to be here, and I hope I can answer your questions and give information that's useful for investors for understanding our pipeline at Regeneron.

Questions and Answers:

Hartaj Singh - Oppenheimer & Co. Inc., Research Division -

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.